Clinical trial
A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00094861 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
- Lead sponsor
- Swedish Orphan Biovitrum
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2005
- Completion date
- January 31, 2014
- Enrollment
- 100 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
dysphagia, lung cancer, non-small cell lung cancer